Form 4: ADMA Biologics EVP, CFO Brian Lenz Reports Stock Disposal to Cover Tax Obligations

Sentiment:

SEC Form 4


Brian Lenz, EVP and CFO of ADMA Biologics, disposed of 4,935 shares of common stock on February 29, 2024, to cover tax obligations related to vesting restricted stock units.

Summary

  • On February 29, 2024, Brian Lenz, the EVP and CFO of ADMA Biologics, disposed of 4,935 shares of common stock.
  • The transaction was executed at a price of $5.36 per share.
  • This disposal was related to covering tax obligations associated with the vesting of restricted stock units (RSUs).
  • Following the transaction, Lenz directly owns 736,644 shares of ADMA Biologics common stock, which includes unvested RSUs and shares acquired through prior purchases and RSU settlements.

Sentiment

Score: 5

Explanation: This is a routine filing related to stock transactions for tax purposes, so the sentiment is neutral.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into insider transactions. The sale of shares to cover tax obligations is a common practice.

Stakeholder Impact

  • The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.

Key Dates

DateDescription
02/25/2021Grant date of 13,750 unvested RSUs that vest quarterly over four years.
09/29/2021Grant date of 123,749 unvested Time-Based RSUs vesting quarterly until December 31, 2024.
03/07/2022Grant date of 103,125 unvested RSUs vesting quarterly over four years.
03/06/2023Grant date of 135,175 RSUs vesting quarterly over four years.
02/29/2024Date of stock disposal transaction.
03/04/2024Date of Form 4 filing.
12/31/2024Date that 123,749 unvested Time-Based RSUs become fully vested.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.